Bladder Cancer News, Research Articles | Cancer Treatment Studies

Bladder Cancer


Latest Bladder Cancer News


Bladder Cancer Surgery Safe Following Neoadjuvant Immunotherapy

Toxicity profile and readmission rates among patients who underwent radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab are in line with previously published series reporting 90-day outcomes after RC with or without neoadjuvant chemotherapy.

Keytruda Approved for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer

The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Novel Gene Therapy Shows Efficacy in BCG-Refractory High-Grade NMIBC

Nadofaragene firadenovec, an adenovirus vector-based gene therapy containing the gene interferon alfa-2b, achieved a complete response in 53% of patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease at 3 months.
AUA 2017, surgeons, bladder cancer procedure, surgery, cancer diversion

Radical Cystectomy Approaches Offer Similar Long-Term Oncologic Outcomes

Laparoscopic, robotic-assisted, and open radical cystectomy are associated with similar long-term oncologic outcomes among patients with muscle-invasive or high-risk nonmuscle-invasive bladder cancer, according to findings from the CORAL study, the only randomized trial comparing the 3 surgical approaches. In the study, investigators randomly assigned patients with muscle-invasive bladder cancer (MIBC, 38 patients) or high-risk non-muscle…
Next post in Bladder Cancer